(Q34288933)

1 August 2017

1 reference

title

The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy (English)

1 reference

1 August 2017

1 reference

Goldenberg DM

1

1 reference

1 August 2017

language of work or name

1 reference

1 July 2001

1 reference

Critical Reviews in Oncology Hematology

1 August 2017

published in

1 reference

1 August 2017

volume

39

1 reference

1 August 2017

issue

1-2

1 reference

1 August 2017

page(s)

195-201

1 reference

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900108-1

7 January 2021

Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900108-1

7 January 2021

Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900108-1

7 January 2021

Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900108-1

7 January 2021

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900108-1

7 January 2021

Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900108-1

7 January 2021

Lymphoma imaging with a new technetium-99m labelled antibody, LL2

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900108-1

7 January 2021

Initial clinical results with technetium-99m-labeled LL2 monoclonal antibody fragment in the radioimmunodetection of B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900108-1

7 January 2021

Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900108-1

7 January 2021

Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900108-1

7 January 2021

Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900108-1

7 January 2021

Radioimmunotherapy of lymphoma: a UC Davis experience

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900108-1

7 January 2021

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900108-1

7 January 2021

Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900108-1

7 January 2021

Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900108-1

7 January 2021

Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900108-1

7 January 2021

10.1016/S1040-8428(01)00108-1

Identifiers

DOI

1 reference

1 August 2017

1 reference